Stifel downgraded Mirati Therapeutics to Hold from Buy with a price target of $59, down from $83.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MRTX:
- Mirati Therapeutics reports Q3 EPS ($2.49), consensus ($2.83)
- Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
- MRTX Earnings Report this Week: Is It a Buy, Ahead of Earnings?
- Mirati Therapeutics receives MHRA approval for KRAZATI
- Kura Oncology, Mirati Therapeutics enter clinical collab, supply agreement